What happened
On August 6, 2026, FDA granted accelerated approval to vusolimogene oderparepvec-wtpg, branded Tudriqev and developed by Replimune, Inc., in combination with nivolumab for adult patients with unresectable advanced cutaneous melanoma whose disease progressed on a programmed death receptor-1, or PD-1, blocking antibody-based regimen. FDA said the product is a genetically modified oncolytic viral therapy, and that the decision was made under the accelerated approval pathway based on objective response rate and duration of response.
The agency evaluated safety and efficacy in the IGNYTE trial, an open-label, multiregional, single-arm study in 140 adult patients with Stage IIIB, IIIC or IV unresectable advanced melanoma who had disease progression on at least eight consecutive weeks of prior anti-PD-1-based therapy. Of those 140 patients, 91 with at least one noninjected lesion were included in the efficacy-evaluable population. In that group, objective response rate was 24.2% with a 95% confidence interval of 15.8 to 34.3, and median duration of response was 14.1 months with a confidence interval of 10.7 to not reached.
FDA also said Replimune must conduct post-approval trial(s) to verify and describe clinical benefit, and continued approval may be contingent on confirmatory trial(s). The combination had received breakthrough therapy designation. Also part of the backdrop, FDA had convened the Cellular, Tissue, and Gene Therapies Advisory Committee on July 30, 2026, to discuss the application.
Why it matters
This is a real regulatory win, but also a tightly bounded one. The label FDA described is for a specific melanoma population, adults with unresectable advanced cutaneous melanoma after progression on a PD-1-blocking regimen, and the approval rests on surrogate measures from a single-arm study, not a randomized demonstration of clinical benefit. That leaves the confirmatory program at the center of the story from here.
The likely read for investors and commercial teams is that approval removes a major overhang, while shifting attention almost immediately to execution, physician uptake in this post-PD-1 setting, and the design and timing of the required post-approval work. For payers, the filing suggests a familiar accelerated-approval dynamic. There is now an FDA-cleared option, but the evidence package cited by the agency is narrower than what many coverage committees prefer, especially because efficacy was assessed in 91 patients from the trial.
Expect scrutiny around patient selection, administration logistics, and adverse-event monitoring, given the warnings and precautions for accidental exposure, herpetic infection or reactivation, injection procedure complications, and immune-mediated events. One practical implication. This should be evaluated as a specialized oncology product rather than a broad melanoma franchise play. For more on specialty drug economics, see RxInfo.ai. For detailed drug monographs, see ClinicalRx.ai.
